Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103

Julie Davies, Jing Chen, Ryan Pink, David Carter, Nigel Saunders, Georgios Sotiriadis, Bo Bai, Yanyou Pan, David Howlett, Annette Payne, Harpal Randeva, Emmanouil Karteris*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Orexins are neuropeptides that regulate the sleep-wake cycle and feeding behaviour. QRFP is a newly discovered neuropeptide which exerts similar orexigenic activity, thus playing an important role in energy homeostasis and regulation of appetite. The exact expression and signalling characteristics and physiological actions of QRFP and its receptor GPR103 are poorly understood. Alzheimerâ €™ s disease (AD) patients experience increased nocturnal activity, excessive daytime sleepiness, and weight loss. We hypothesised therefore that orexins and QRFP might be implicated in the pathophysiology of AD. We report that the down-regulation of hippocampal orexin receptors (OXRs) and GPR103 particularly in the cornu ammonis (CA) subfield from AD patients suffering from early onset familial AD (EOFAD) and late onset familial AD (LOAD). Using an in vitro model we demonstrate that this downregulation is due to to Aβ-plaque formation and tau hyper-phosphorylation. Transcriptomics revealed a neuroprotective role for both orexins and QRFP. Finally we provide conclusive evidence using BRET and FRET that OXRs and GPR103 form functional hetero-dimers to exert their effects involving activation of ERK 1/2. Pharmacological intervention directed at the orexigenic system may prove to be an attractive avenue towards the discovery of novel therapeutics for diseases such as AD and improving neuroprotective signalling pathways.

Original languageEnglish
Article number12584
Number of pages12
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - 30 Jul 2015

Fingerprint

Orexin Receptors
Neuroprotective Agents
Alzheimer Disease
Neuropeptides
Down-Regulation
Appetite Regulation
Feeding Behavior
Weight Loss
Hippocampus
Sleep
Homeostasis
Phosphorylation
Pharmacology

Bibliographical note

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Supplementary information: http://www.nature.com/srep

Cite this

Davies, J., Chen, J., Pink, R., Carter, D., Saunders, N., Sotiriadis, G., ... Karteris, E. (2015). Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. Scientific Reports, 5, [12584]. https://doi.org/10.1038/srep12584
Davies, Julie ; Chen, Jing ; Pink, Ryan ; Carter, David ; Saunders, Nigel ; Sotiriadis, Georgios ; Bai, Bo ; Pan, Yanyou ; Howlett, David ; Payne, Annette ; Randeva, Harpal ; Karteris, Emmanouil. / Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. In: Scientific Reports. 2015 ; Vol. 5.
@article{9ff9fba1bc634e4a8363fb741d0b7f7b,
title = "Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103",
abstract = "Orexins are neuropeptides that regulate the sleep-wake cycle and feeding behaviour. QRFP is a newly discovered neuropeptide which exerts similar orexigenic activity, thus playing an important role in energy homeostasis and regulation of appetite. The exact expression and signalling characteristics and physiological actions of QRFP and its receptor GPR103 are poorly understood. Alzheimer{\^a} €™ s disease (AD) patients experience increased nocturnal activity, excessive daytime sleepiness, and weight loss. We hypothesised therefore that orexins and QRFP might be implicated in the pathophysiology of AD. We report that the down-regulation of hippocampal orexin receptors (OXRs) and GPR103 particularly in the cornu ammonis (CA) subfield from AD patients suffering from early onset familial AD (EOFAD) and late onset familial AD (LOAD). Using an in vitro model we demonstrate that this downregulation is due to to Aβ-plaque formation and tau hyper-phosphorylation. Transcriptomics revealed a neuroprotective role for both orexins and QRFP. Finally we provide conclusive evidence using BRET and FRET that OXRs and GPR103 form functional hetero-dimers to exert their effects involving activation of ERK 1/2. Pharmacological intervention directed at the orexigenic system may prove to be an attractive avenue towards the discovery of novel therapeutics for diseases such as AD and improving neuroprotective signalling pathways.",
author = "Julie Davies and Jing Chen and Ryan Pink and David Carter and Nigel Saunders and Georgios Sotiriadis and Bo Bai and Yanyou Pan and David Howlett and Annette Payne and Harpal Randeva and Emmanouil Karteris",
note = "This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Supplementary information: http://www.nature.com/srep",
year = "2015",
month = "7",
day = "30",
doi = "10.1038/srep12584",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Davies, J, Chen, J, Pink, R, Carter, D, Saunders, N, Sotiriadis, G, Bai, B, Pan, Y, Howlett, D, Payne, A, Randeva, H & Karteris, E 2015, 'Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103', Scientific Reports, vol. 5, 12584. https://doi.org/10.1038/srep12584

Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. / Davies, Julie; Chen, Jing; Pink, Ryan; Carter, David; Saunders, Nigel; Sotiriadis, Georgios; Bai, Bo; Pan, Yanyou; Howlett, David; Payne, Annette; Randeva, Harpal; Karteris, Emmanouil.

In: Scientific Reports, Vol. 5, 12584, 30.07.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103

AU - Davies, Julie

AU - Chen, Jing

AU - Pink, Ryan

AU - Carter, David

AU - Saunders, Nigel

AU - Sotiriadis, Georgios

AU - Bai, Bo

AU - Pan, Yanyou

AU - Howlett, David

AU - Payne, Annette

AU - Randeva, Harpal

AU - Karteris, Emmanouil

N1 - This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Supplementary information: http://www.nature.com/srep

PY - 2015/7/30

Y1 - 2015/7/30

N2 - Orexins are neuropeptides that regulate the sleep-wake cycle and feeding behaviour. QRFP is a newly discovered neuropeptide which exerts similar orexigenic activity, thus playing an important role in energy homeostasis and regulation of appetite. The exact expression and signalling characteristics and physiological actions of QRFP and its receptor GPR103 are poorly understood. Alzheimerâ €™ s disease (AD) patients experience increased nocturnal activity, excessive daytime sleepiness, and weight loss. We hypothesised therefore that orexins and QRFP might be implicated in the pathophysiology of AD. We report that the down-regulation of hippocampal orexin receptors (OXRs) and GPR103 particularly in the cornu ammonis (CA) subfield from AD patients suffering from early onset familial AD (EOFAD) and late onset familial AD (LOAD). Using an in vitro model we demonstrate that this downregulation is due to to Aβ-plaque formation and tau hyper-phosphorylation. Transcriptomics revealed a neuroprotective role for both orexins and QRFP. Finally we provide conclusive evidence using BRET and FRET that OXRs and GPR103 form functional hetero-dimers to exert their effects involving activation of ERK 1/2. Pharmacological intervention directed at the orexigenic system may prove to be an attractive avenue towards the discovery of novel therapeutics for diseases such as AD and improving neuroprotective signalling pathways.

AB - Orexins are neuropeptides that regulate the sleep-wake cycle and feeding behaviour. QRFP is a newly discovered neuropeptide which exerts similar orexigenic activity, thus playing an important role in energy homeostasis and regulation of appetite. The exact expression and signalling characteristics and physiological actions of QRFP and its receptor GPR103 are poorly understood. Alzheimerâ €™ s disease (AD) patients experience increased nocturnal activity, excessive daytime sleepiness, and weight loss. We hypothesised therefore that orexins and QRFP might be implicated in the pathophysiology of AD. We report that the down-regulation of hippocampal orexin receptors (OXRs) and GPR103 particularly in the cornu ammonis (CA) subfield from AD patients suffering from early onset familial AD (EOFAD) and late onset familial AD (LOAD). Using an in vitro model we demonstrate that this downregulation is due to to Aβ-plaque formation and tau hyper-phosphorylation. Transcriptomics revealed a neuroprotective role for both orexins and QRFP. Finally we provide conclusive evidence using BRET and FRET that OXRs and GPR103 form functional hetero-dimers to exert their effects involving activation of ERK 1/2. Pharmacological intervention directed at the orexigenic system may prove to be an attractive avenue towards the discovery of novel therapeutics for diseases such as AD and improving neuroprotective signalling pathways.

UR - http://www.scopus.com/inward/record.url?scp=84938331166&partnerID=8YFLogxK

U2 - 10.1038/srep12584

DO - 10.1038/srep12584

M3 - Article

AN - SCOPUS:84938331166

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 12584

ER -